Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 10, 2009, Pages 1617-1624

  Choi, Kee Don ^a,b   Kim, Nayoung ^b,d   Jang, In Jin ^c   Park, Young Soo ^b,d   Cho, Joo Youn ^c   Kim, Jung Ryul ^c   Shin, Jai Moo ^e,f   Jung, Hyun Chae ^b   Song, In Sung ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

CYP2C19; Helicobacter pylori; Intravenous infusions; Peptic ulcer bleeding; Proton pump inhibitor

Indexed keywords

PANTOPRAZOLE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENDOSCOPIC SURGERY; FEMALE; GASTRIC PH MONITORING; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HEMOSTASIS; HUMAN; KOREA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 70349656640     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05939.x     Document Type: Article

References (32)

1. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996 38 : 316 321.
2. Green FW, Jr., Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978 74 : 38 43.
3. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP. Clot lysis by gastric juice: an in vitro study. Gut 1989 30 : 1704 1707.
4. Brunner G, Luna P, Hartmann M, Wurst W. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale J. Biol. Med. 1996 69 : 225 231.
5. Udd M, Miettinen P, Palmu A et al. Regular-dose versus high-dose omeprazole in peptic ulcer bleeding: a prospective randomized double-blind study. Scand. J. Gastroenterol. 2001 36 : 1332 1338.
6. Kang JM, Kim N, Lee DH et al. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J. Gastroenterol. Hepatol. 2008 23 : 1287 1291.
7. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab. Pharmacokinet. 2005 20 : 153 167.
8. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 1994 46 : 594 598. (Pubitemid 24334747)
9. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 1994 269 : 15419 15422.
10. Furuta T, Ohashi K, Kosuge K et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 1999 65 : 552 561.
11. Horai Y, Kimura M, Furuie H et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment. Pharmacol. Ther. 2001 15 : 793 803.
12. Sugimoto M, Furuta T, Shirai N et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin. Pharmacol. Ther. 2004 76 : 290 301.
13. Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. 2002 16 : 1811 1817.
14. Lim PW, Goh KL, Wong BC. CYP2C19 genotype and the PPIs - focus on rabeprazole. J. Gastroenterol. Hepatol. 2005 20 (Suppl. S22 8.
15. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin. Pharmacol. Ther. 2001 70 : 484 492.
16. Han KS, Choi HC, Yoo JK, Lee JW, Lee MG. Determination of a new proton pump inhibitor, YH1885, in human plasma and urine by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1997 696 : 312 316.
17. Yu KS, Bae KS, Shon JH et al. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J. Clin. Pharmacol. 2004 44 : 73 82.
18. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 1996 60 : 661 666.
19. van Rensburg CJ, Hartmann M, Thorpe A et al. Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer. Am. J. Gastroenterol. 2003 98 : 2635 2641.
20. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia - a post hoc analysis from the Cochrane Collaboration. Aliment. Pharmacol. Ther. 2005 21 : 1055 1061.
21. Lam SK, Hasan M, Sircus W, Wong J, Ong GB, Prescott RJ. Comparison of maximal acid output and gastrin response to meals in Chinese and Scottish normal and duodenal ulcer subjects. Gut 1980 21 : 324 328.
22. Caraco Y, Lagerstrom PO, Wood AJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin. Pharmacol. Ther. 1996 60 : 157 167.
23. Verdu EF, Armstrong D, Fraser R et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995 36 : 539 543.
24. Beil W, Birkholz C, Wagner S, Sewing KF. Interaction of Helicobacter pylori and its fatty acids with parietal cells and gastric H+/K(+)-ATPase. Gut 1994 35 : 1176 1180.
25. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand. J. Gastroenterol. 1994 29 : 425 429.
26. Wallace JL, Cucala M, Mugridge K, Parente L. Secretagogue-specific effects of interleukin-1 on gastric acid secretion. Am. J. Physiol. 1991 261 : G559 64.
27. Haruma K, Mihara M, Okamoto E et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment. Pharmacol. Ther. 1999 13 : 155 162.
28. Kim N, Park YS, Cho SI et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter 2008 13 : 245 255.
29. Naylor GM, Gotoda T, Dixon M et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut 2006 55 : 1545 1552.
30. Barkun A, Bardou M, Marshall JK. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann. Intern. Med. 2003 139 : 843 857.
31. Andriulli A, Annese V, Caruso N et al. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. Am. J. Gastroenterol. 2005 100 : 207 219.
32. Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun AN. Meta-analysis proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment. Pharmacol. Ther. 2005 21 : 677 686.